Pharmacogenetics in the treatment of chronic lymphocytic leukemia: what does the future hold?

被引：1
作者：
Johnson, Gillian G. [1 ,2 ]
Carr, Daniel F. [3 ]
Pirmohamed, Munir [3 ]
Pettitt, Andrew R. [2 ]
机构：
[1] Royal Liverpool & Broadgreen Univ Hosp Trust, Dept Haematol, Liverpool, Merseyside, England
[2] Univ Liverpool, Dept Mol & Clin Canc Med, Liverpool L69 3BX, Merseyside, England
[3] Univ Liverpool, Dept Mol & Clin Pharmacol, Liverpool L69 3BX, Merseyside, England
来源：
PHARMACOGENOMICS | 2014年 / 15卷 / 07期
基金：
英国医学研究理事会;
关键词：
adverse drug reactions; bendamustine; chronic lymphocytic leukemia; cyclophosphamide; fludarabine; personalized medicine; pharmacogenomics; GENETIC-POLYMORPHISM; UNTREATED PATIENTS; HUMAN LIVER; RITUXIMAB; CYCLOPHOSPHAMIDE; BENDAMUSTINE; CHLORAMBUCIL; FLUDARABINE; EXPRESSION; VARIANTS;
D O I：
10.2217/pgs.14.60
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
[No abstract available]
引用
收藏
页码：897 / 900
页数：4
相关论文
共 50 条
  • [41] Short communication: bendamustine-related hemolytic anemia in chronic lymphocytic leukemia
    Goldschmidt, Neta
    Gural, Alexander
    Ben-Yehuda, Dina
    Gatt, Moshe E.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (03) : 709 - 713
  • [42] Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE study
    Chaoui, Driss
    Choquet, Sylvain
    Sanhes, Laurence
    Mahe, Beatrice
    Hacini, Maya
    Fitoussi, Olivier
    Arkam, Yazid
    Orfeuvre, Hubert
    Dilhuydy, Marie-Sarah
    Barry, Marly
    Jourdan, Eric
    Dreyfus, Brigitte
    Tempescul, Adrian
    Lepretre, Stephane
    Bardet, Aurelie
    Leconte, Pierre
    Maynadie, Marc
    Delmer, Alain
    LEUKEMIA & LYMPHOMA, 2017, 58 (06) : 1366 - 1375
  • [43] Impact of Oral Targeted Therapy on the Economic Burden of Chronic Lymphocytic Leukemia in Canada
    Lachaine, Jean
    Beauchemin, Catherine
    Guinan, Kimberly
    Thebault, Philippe
    Aw, Andrew
    Banerji, Versha
    Fleury, Isabelle
    Owen, Carolyn
    CURRENT ONCOLOGY, 2021, 28 (01) : 332 - 345
  • [44] Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients
    Montillo, Marco
    Tedeschi, Alessandra
    Gaidano, Gianluca
    Coscia, Marta
    Petrizzi, Valeria Belsito
    Orlandi, Ester
    Cascavilla, Nicola
    Ghia, Paolo
    Motta, Marina
    Gallamini, Andrea
    Frustaci, Anna Maria
    Rossi, Davide
    De Paoli, Lorenzo
    Nichelatti, Michele
    Morra, Enrica
    Massaia, Massimo
    HAEMATOLOGICA, 2014, 99 (09) : E159 - E161
  • [45] Obinutuzumab: its use in the management of chronic lymphocytic leukemia
    Arnason, Jon E.
    Brown, Jennifer R.
    EXPERT OPINION ON ORPHAN DRUGS, 2015, 3 (07): : 843 - 853
  • [46] Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma
    Costa, Luciano J.
    Fanning, Suzanne R.
    Stephenson, Joe, Jr.
    Afrin, Lawrence B.
    Kistner-Griffin, Emily
    Bentz, Tricia A.
    Stuart, Robert K.
    LEUKEMIA & LYMPHOMA, 2015, 56 (03) : 645 - 649
  • [47] Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab
    Zent, Clive S.
    Wu, Wenting
    Bowen, Deborah A.
    Hanson, Curtis A.
    Pettinger, Adam M.
    Shanafelt, Tait D.
    Kay, Neil E.
    Leis, Jose F.
    Call, Timothy G.
    LEUKEMIA & LYMPHOMA, 2013, 54 (03) : 476 - 482
  • [48] Is this the end for immunochemotherapy in relapsed/refractory chronic lymphocytic leukemia?
    Robak, Tadeusz
    LEUKEMIA & LYMPHOMA, 2023, 64 (05) : 907 - 909
  • [49] Polymorphisms and haplotypes in multidrug resistance 1 gene are not associated with chronic lymphocytic leukemia susceptibility and prognostic parameters of chronic lymphocytic leukemia in Chinese population
    Dong, Hua-Jie
    Miao, Kou-Rong
    Qiao, Chun
    Zhuang, Yun
    Shen, Wen-Yi
    Hong, Ming
    Fan, Lei
    Liu, Peng
    Xu, Wei
    Li, Jian-Yong
    LEUKEMIA & LYMPHOMA, 2011, 52 (06) : 1003 - 1009
  • [50] The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars
    Brown, Jennifer R.
    Cymbalista, Florence
    Sharman, Jeff
    Jacobs, Ira
    Nava-Parada, Pilar
    Mato, Anthony
    ONCOLOGIST, 2018, 23 (03) : 288 - 296
12345